141 related articles for article (PubMed ID: 28225406)
1. Antibiotics.
Dalal KS; Bridgeman MB
Nursing; 2017 Mar; 47(3):70. PubMed ID: 28225406
[No Abstract] [Full Text] [Related]
2. Dalbavancin, tedizolid phosphate, oritavancin diphosphate, and vedolizumab.
Hussar DA; Nguyen A
J Am Pharm Assoc (2003); 2014; 54(6):658-62. PubMed ID: 25379985
[No Abstract] [Full Text] [Related]
3. Three new agents added to the arsenal to fight MRSA.
Strain J
S D Med; 2014 Dec; 67(12):513-4. PubMed ID: 25571620
[No Abstract] [Full Text] [Related]
4. Current and future trends in antibiotic therapy of acute bacterial skin and skin-structure infections.
Russo A; Concia E; Cristini F; De Rosa FG; Esposito S; Menichetti F; Petrosillo N; Tumbarello M; Venditti M; Viale P; Viscoli C; Bassetti M
Clin Microbiol Infect; 2016 Apr; 22 Suppl 2():S27-36. PubMed ID: 27125562
[TBL] [Abstract][Full Text] [Related]
5. New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
Li R; Nailor MD
Conn Med; 2016 Mar; 80(3):175-80. PubMed ID: 27169303
[TBL] [Abstract][Full Text] [Related]
6. Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2018 Oct; 43(10):31-37. PubMed ID: 30153191
[TBL] [Abstract][Full Text] [Related]
7. New drugs 2015, part 2.
Hussar DA
Nursing; 2015 Jul; 45(7):34-41; quiz 41-2. PubMed ID: 26083291
[No Abstract] [Full Text] [Related]
8. Antimicrobial development in the era of emerging resistance.
Sorlozano A; Carrasco C; Cabeza J; Villegas E; Gutierrez J
Mini Rev Med Chem; 2009 Jul; 9(8):938-55. PubMed ID: 19601889
[TBL] [Abstract][Full Text] [Related]
9. New antibiotics in the management of acute bacterial skin and skin structure infections.
Gleghorn K; Grimshaw E; Kelly EK
Skin Therapy Lett; 2015; 20(5):7-9. PubMed ID: 26382907
[TBL] [Abstract][Full Text] [Related]
10. Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.
Bell AM; King ST; Barber KE; Adcock KG; Wagner JL; Stover KR
Nurse Pract; 2017 May; 42(5):1-6. PubMed ID: 28406838
[TBL] [Abstract][Full Text] [Related]
11. Dalbavancin (Dalvance) for the treatment of acute bacterial skin infection.
Gupta AK; Foley KA; Abramovits W; Rosen T
Skinmed; 2014; 12(6):366-9. PubMed ID: 25823083
[No Abstract] [Full Text] [Related]
12. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections.
Roberts KD; Sulaiman RM; Rybak MJ
Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480
[TBL] [Abstract][Full Text] [Related]
13. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
Guskey MT; Tsuji BT
Pharmacotherapy; 2010 Jan; 30(1):80-94. PubMed ID: 20030476
[TBL] [Abstract][Full Text] [Related]
14. Dalbavancin approved for acute skin infections.
Traynor K
Am J Health Syst Pharm; 2014 Jul; 71(13):1062. PubMed ID: 24939490
[No Abstract] [Full Text] [Related]
15. Two new drugs for skin and skin structure infections.
Med Lett Drugs Ther; 2014 Aug; 56(1449):73-5. PubMed ID: 25118799
[No Abstract] [Full Text] [Related]
16. Antibiotics for skin infections: new study design and a step toward shorter course therapy.
Doron S; Boucher HW
JAMA; 2013 Feb; 309(6):609-11. PubMed ID: 23403687
[No Abstract] [Full Text] [Related]
17. New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
Crotty MP; Krekel T; Burnham CA; Ritchie DJ
J Clin Microbiol; 2016 Sep; 54(9):2225-32. PubMed ID: 26962092
[TBL] [Abstract][Full Text] [Related]
18. End points in trials of treatments for skin infections.
Spellberg B
JAMA; 2013 May; 309(20):2091-2. PubMed ID: 23695471
[No Abstract] [Full Text] [Related]
19. End points in trials of treatments for skin infections--reply.
Prokocimer P; Das A
JAMA; 2013 May; 309(20):2092. PubMed ID: 23695472
[No Abstract] [Full Text] [Related]
20. FDA approves Dalvance to treat skin infections.
Clin Infect Dis; 2014 Jul; 59(2):i. PubMed ID: 25105184
[No Abstract] [Full Text] [Related]
[Next] [New Search]
